MBMarzio Bevilacqua
Marzio Bevilacqua
*This is an algorithmically generated author record based on publicly available information.
Research Subjects
Marzio Bevilacqua has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Gori
Anesthesiology and Intensive Care Unit, Morgagni Pierantoni Hospital, AUSL Romagna, 47121 Forlì, Italy
1 shared publication - Angela Gioia
Hospice, UF Cure Palliative, Azienda USL Toscana NordOvest, Pisa, Italy
1 shared publication - Boaz Gedaliahu Samolsky Dekel
Critical Care Nursing Master Course, University of Bologna, Bologna, Italy; IRCCS AziendaOspedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy
1 shared publication - Giuseppe Casale
Clinical Director Palliative Care Center , Fondazione Policlinico Universitario Campus Bio-Medico , Rome , Italy
1 shared publication - Marco Gunnellini
Medical Oncology, Usl Umbria 1, Perugia, Italy
1 shared publication - Mariacristina Di Marco
Department of Specialized, Experimental, and Diagnostic Medicine, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy, Bologna, Italy
1 shared publication
Latest Publications
- Open Access
- 6 June 2021
- Published by Springer Nature in Pain and Therapy
- Vol. 10 (2) , 1171-1188
The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study
Introduction The literature lacks formally validated and reliable tools for the diagnosis of breakthrough cancer pain (BTcP). The Italian Questionnaire for BTcP diagnosis (IQ-BTP) is an 11-item questionnaire aimed at detecting potential-BTP and classifying it into three likelihood classes: high, intermediate, and low. Methods A multicenter, prospective, and observational study was designed to validate the IQ-BTP. In three consecutive visits with each cancer patient, the demographic and clinical details of the patient, the Brief Pain Inventory (BPI) scores, IQ-BTP outcomes, and clinicians' autonomous BTcP diagnosis (gold standard) and the agreement of this diagnosis with IQ-BTP outcomes were recorded. The assessed domains for IQ-BTP validation were: Validity, including content and face validity, construct validity (hypothesis testing, and cross‐cultural validity\measurement invariance), and criterion validity; Reliability (internal consistency, reliability, and measurement error); Interpretability, and Responsiveness. Results Seven palliative and pain management facilities in Italy recruited 280 patients, yielding 753 evaluations. Using the IQ-BTP, the rate of potential-BTcP was 27.2%, of which its likely presence was high in 52.7% of patients, intermediate in 38.5, and low in 8.8%. The BPI item scores differed significantly between the two IQ-BTP classes (no-BTcP and potential-BTcP classes). The correlation of the latter class with BPI items was significant but low. The IQ-BTcP showed two principal components, accounting for 66.6% of the variance. Cronbach’s α was 0.71. The agreement rate between the gold standard and IQ-BTP outcomes was 82%. Cohen's \(\kappa\) was 0.535. The IQ-BTP showed sensitivity and specificity of 69 and 86%, respectively. Conclusions The IQ-BTP extensive formal validation showed satisfactory psychometric and validity properties. Its content, face, construct, and criterion validities and its reliability, interpretability, and responsiveness were shown. Its use enabled potential-BTcP to be identified and differentiated into three likelihood classes with direct therapeutic and epidemiological implications. The latter may be confirmed in future studies.- 6 June 2021
- Published by Springer Nature in Pain and Therapy
- Vol. 10 (2) , 1171-1188
Open AccessThe Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study
Introduction The literature lacks formally validated and reliable tools for the diagnosis of breakthrough cancer pain (BTcP). The Italian Questionnaire for BTcP diagnosis (IQ-BTP) is an 11-item questionnaire aimed at detecting potential-BTP and classifying it into three likelihood classes: high, intermediate, and low. Methods A multicenter, prospective, and observational study was designed to validate the IQ-BTP. In three consecutive visits with each cancer patient, the demographic and clinical details of the patient, the Brief Pain Inventory (BPI) scores, IQ-BTP outcomes, and clinicians' autonomous BTcP diagnosis (gold standard) and the agreement of this diagnosis with IQ-BTP outcomes were recorded. The assessed domains for IQ-BTP validation were: Validity, including content and face validity, construct validity (hypothesis testing, and cross‐cultural validity\measurement invariance), and criterion validity; Reliability (internal consistency, reliability, and measurement error); Interpretability, and Responsiveness. Results Seven palliative and pain management facilities in Italy recruited 280 patients, yielding 753 evaluations. Using the IQ-BTP, the rate of potential-BTcP was 27.2%, of which its likely presence was high in 52.7% of patients, intermediate in 38.5, and low in 8.8%. The BPI item scores differed significantly between the two IQ-BTP classes (no-BTcP and potential-BTcP classes). The correlation of the latter class with BPI items was significant but low. The IQ-BTcP showed two principal components, accounting for 66.6% of the variance. Cronbach’s α was 0.71. The agreement rate between the gold standard and IQ-BTP outcomes was 82%. Cohen's \(\kappa\) was 0.535. The IQ-BTP showed sensitivity and specificity of 69 and 86%, respectively. Conclusions The IQ-BTP extensive formal validation showed satisfactory psychometric and validity properties. Its content, face, construct, and criterion validities and its reliability, interpretability, and responsiveness were shown. Its use enabled potential-BTcP to be identified and differentiated into three likelihood classes with direct therapeutic and epidemiological implications. The latter may be confirmed in future studies.